" "
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Launches TruSight™ Targeted Sequencing Content Sets

Published: Friday, February 01, 2013
Last Updated: Friday, February 01, 2013
Bookmark and Share
Expert-designed content enables labs to realize benefits of next-generation sequencing.

Illumina, Inc. has announced five initial TruSight content sets for use in next-generation sequencing (NGS) in laboratory settings. Designed by recognized experts at leading institutions, the content sets offer cost-effective, streamlined, targeted sequencing for specific genetic diseases or conditions.

Customers can immediately leverage this content to develop their own tests, and in the first half of 2013 will have the additional capability to augment the sets with custom content.

These products, developed in conjunction with leading healthcare experts including Children's Mercy Center for Pediatric Genomic Medicine, Kennedy Krieger Institute, The Institute of Cancer Research, London, and Partners HealthCare (see additional Illumina-Partners HealthCare news today), are designed to provide comprehensive evaluation of genes associated with the following:

• TruSight Autism used for the evaluation of autism, a condition affecting about 1 in 88 children;
• TruSight Cancer assists in identifying genetic causes of cancer and includes genes associated with common (e.g. breast, colorectal cancer) and rare cancers;
• TruSight Cardiomyopathy assists in identifying inherited causes of cardiomyopathy;
• TruSight Inherited Disease focuses on severe, recessive pediatric onset diseases; and
• TruSight Exome targets rare genetic diseases that affect as many as 10 million people per year worldwide, with content from the HGMD® (Human Gene Mutation Database).

"The launch of these new NGS products is an exciting milestone for Illumina," said Jay Flatley, President and Chief Executive Officer for Illumina.

Flatley continued, "We worked closely with the community to develop and introduce these first content sets, to ensure we are meeting the needs of laboratories and to enable results of high quality. Combining this content with already proven Illumina next-generation sequencing technology, via the MiSeq® platform, will provide a powerful tool."

TruSight content sets are comprised of oligo probes that target specific genes and regions relevant to specific diseases or conditions. They are designed for use by laboratories in the development of their own unique targeted sequencing tests and will work on Illumina's MiSeq system.

Additionally, new Nextera Enrichment kits and MiSeq kits will support lower sample throughput options.

"We are very excited about the value of the new content and how accessible it will be to laboratories," said Dr. Stephen Kingsmore, Director, Children's Mercy Center for Pediatric Genomic Medicine, in Kansas City, Mo. "Deploying this expert content on Illumina's proven technology streamlines a lab's operational efficiency and speed to results. Ultimately, we hope to improve patient care. That's the true goal."

Added Matt Posard, Senior Vice President and General Manager of Illumina's Translational and Consumer Genomics business, "Today, Illumina also announced a strategic alliance with Partners HealthCare to introduce next-generation sequencing clinical interpretation and reporting tools, via their GeneInsight® Suite platform. The combination of TruSight products and these new interpretation and reporting tools is a major step forward in realizing the benefits of next generation sequencing."

TruSight content sets are for research use only and not intended for diagnostic use. The products are now available for order with shipment to begin in Q4 2012.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Signs Multiple Biobank Deals
MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Wednesday, February 03, 2016
Illumina Acquires Conexio Genomics
Acquisition strengthens company’s ability to deliver sample-to-report solutions for HLA typing.
Wednesday, January 27, 2016
Illumina Forms New Company
GRAIL to enable early cancer detection via blood-based screening.
Tuesday, January 12, 2016
Bio-Rad, Illumina Partner
Scalable, high-throughput platform to offer unprecedented insight into gene expression of individual cells.
Tuesday, January 12, 2016
Novogene and Illumina Enters into Agreement
Agreement to co-develop NGS diagnostic system for reproductive health and oncology applications.
Wednesday, December 16, 2015
bioMérieux and Illumina Announce the Launch of bioMérieux EpiSeq™
A revolutionary next-generation sequencing service for epidemiological monitoring of bacterial infections.
Tuesday, December 15, 2015
Illumina Accelerator Announces Third Funding Cycle of Genomics Startups
Invests in synthetic biology, reproductive health, skin microbiome and nutrition startups.
Thursday, December 10, 2015
Desktop Genetics Receives Strategic Investment from Illumina
Illumina invests in Desktop Genetics' technology to support the platform's integration with NGS pipelines and improve CRISPR genome editing workflows.
Thursday, December 10, 2015
Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
MSK and Illumina Launch Comprehensive Circulating Tumor DNA Program
Collaboration aims to determine range of opportunities for non-invasive cancer diagnosis and monitoring.
Thursday, September 17, 2015
Illumina Completes Acquisition of GenoLogics
Illumina’s to drive the adoption of sequencing in new markets and improve the genomic workflow.
Wednesday, September 02, 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix
LabCorp to be initial strategic partner in development of consumer applications.
Tuesday, August 18, 2015
Illumina Accelerator Invests in Second Class of Genomics Startups
Startups selected from Spain, Oregon, and California to advance breakthrough applications.
Thursday, August 06, 2015
Scientific News
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Validating the Accuracy of CRISPR-Cas9
IBS Researchers create multiplex Digenome-seq to find errors in CRISPR-Cas9 processes.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!